Literature DB >> 11471487

Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results.

G Paganelli1, M Bartolomei, M Ferrari, M Cremonesi, G Broggi, G Maira, C Sturiale, C Grana, G Prisco, M Gatti, P Caliceti, M Chinol.   

Abstract

The aim of this study was to determine the maximum-tolerated dose, of a pre-targeting three-step (3-S) method employing 90Y-biotin in the locoregional radioimmunotherapy (RIT) of recurrent high grade glioma, and to investigate the antitumor efficacy of this new treatment. Twenty-four patients with recurrent glioma underwent second surgical debulking and implantation of a catheter into the surgical resection cavity (SRC), in order to introduce the radioimmunotherapeutic agents [biotinylated monoclonal antibody (MoAb), avidin and 90Y-biotin]. Eight patients with anaplastic astrocytoma (AA) and 16 patients with glioblastoma (GBM) were injected with biotinylated anti-tenascin MoAb (2 mg), then with avidin (10 mg; 24 h later) and finally 90Y-biotin (18 h later). Each patient received two of these treatments 8-10 weeks apart. The injected activity ranged from 0.555 to 1.110 GBq (15-30 mCi). Dosage was escalated by 0.185 GBq (5 mCi) in four consecutive groups. The treatment was well tolerated without acute side effects up to 0.740 GBq (20 mCi). The maximum tolerated activity was 1.110 GBq (30 mCi) limited by neurological toxicity. None of the patients developed hematologic toxicity. In three patients infection occurred around the catheter. The average absorbed dose to the normal brain was minimal compared with that received at the SRC interface. At first control (after 2 months), partial (PR) and minor (MR) responses were observed in three GBM (1 PR; 2 MR) and three AA patients (1 PR; 2 MR) with an overall objective response rate of 25%. Stable disease (SD) was achieved in seven GBM and five AA patients (50%). There was disease progression in six GBM patients (25%), but in none of the AA patients. At the dosage of 0.7-0.9 GBq per cycle, locoregional 3-S-RIT was safe and produced an objective response in 25% of patients. Based on these encouraging results, phase II studies employing 3-S-RIT soon after first debulking are justified.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11471487     DOI: 10.1089/10849780152389410

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  34 in total

1.  Treatment of cultured glioma cells with the EGFR-TKI gefitinib ("Iressa", ZD1839) increases the uptake of astatinated EGF despite the absence of gefitinib-mediated growth inhibition.

Authors:  Asa Liljegren Sundberg; Ylva Almqvist; Vladimir Tolmachev; Jörgen Carlsson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-07       Impact factor: 9.236

2.  Challenging semi-bootstrapping molecular-replacement strategy reveals intriguing crystal packing of rhizavidin.

Authors:  Amit Meir; Oded Livnah
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2010-03-26

3.  Magnetic resonance imaging visualization of targeted cells by the internalization of supramolecular adducts formed between avidin and biotinylated Gd3+ chelates.

Authors:  Simonetta Geninatti Crich; Alessandro Barge; Elisa Battistini; Claudia Cabella; Sara Coluccia; Dario Longo; Valentina Mainero; Guido Tarone; Silvio Aime
Journal:  J Biol Inorg Chem       Date:  2004-12-23       Impact factor: 3.358

Review 4.  Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.

Authors:  C Andrew Boswell; Martin W Brechbiel
Journal:  Nucl Med Biol       Date:  2007-06-08       Impact factor: 2.408

Review 5.  Planning for intracavitary anti-EGFR radionuclide therapy of gliomas. Literature review and data on EGFR expression.

Authors:  J Carlsson; Z P Ren; K Wester; A L Sundberg; N E Heldin; G Hesselager; M Persson; L Gedda; V Tolmachev; H Lundqvist; E Blomquist; M Nistér
Journal:  J Neurooncol       Date:  2006-03       Impact factor: 4.130

6.  Design, characterization, and intracellular trafficking of biofunctionalized chitosan nanomicelles.

Authors:  Weiyi Li; Giulia Suarato; Jillian M Cathcart; Paul R Sargunas; Yizhi Meng
Journal:  Biointerphases       Date:  2020-11-13       Impact factor: 2.456

Review 7.  Delivery of local therapeutics to the brain: working toward advancing treatment for malignant gliomas.

Authors:  Kaisorn L Chaichana; Leon Pinheiro; Henry Brem
Journal:  Ther Deliv       Date:  2015-03

8.  Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?

Authors:  Amerigo Boiardi; Antonio Silvani; Marica Eoli; Elena Lamperti; Andrea Salmaggi; Paola Gaviani; Anna Fiumani; Andrea Botturi; Chiara Falcone; Alessandra Solari; Graziella Filippini; Francesco Di Meco; Giovanni Broggi
Journal:  J Neurooncol       Date:  2008-02-19       Impact factor: 4.130

9.  Intraoperative avidination for radionuclide treatment as a radiotherapy boost in breast cancer: results of a phase II study with (90)Y-labeled biotin.

Authors:  Giovanni Paganelli; Concetta De Cicco; Mahila E Ferrari; Giuseppe Carbone; Gianmatteo Pagani; Maria Cristina Leonardi; Marta Cremonesi; Annamaria Ferrari; Monica Pacifici; Amalia Di Dia; Rita De Santis; Viviana Galimberti; Alberto Luini; Roberto Orecchia; Stefano Zurrida; Umberto Veronesi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-04       Impact factor: 9.236

Review 10.  Gadolinium-based contrast agents for magnetic resonance cancer imaging.

Authors:  Zhuxian Zhou; Zheng-Rong Lu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2012-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.